CHMP recommends Bayer ’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has recommended darolutamide, an oral androgen receptor inhibitor (ARi), plus ADT in combination with docetaxel for marketing authorization in the European Union (EU) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). (Source: World Pharma News)
Source: World Pharma News - January 30, 2023 Category: Pharmaceuticals Tags: Featured Bayer Business and Industry Source Type: news

‘Erythoplakia’ in the mouth could signal a high cancer risk - signs to spot while flossing
The precancerous lesions may also alter the sound of a person's voice. (Source: Daily Express - Health)
Source: Daily Express - Health - January 28, 2023 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news

Is There Really No Safe Amount of Drinking?
The safest amount of alcohol to drink is none, according to new guidance from the Canadian Centre on Substance Use and Addiction. That’s a marked change from Canada’s previous national guidance on alcohol consumption, which advised women to have no more than 10 drinks per week and men no more than 15. By contrast, the new report says those who drink only one or two boozy beverages per week “will likely avoid” alcohol-related health consequences including chronic diseases, liver injury, and accidents—but the safest choice, it says, is not to drink at all. [time-brightcove not-tgx=”true...
Source: TIME: Health - January 19, 2023 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Diet & Nutrition healthscienceclimate Source Type: news

Difficulty moving your jaw could signal certain disorders and even cancer, dentist warns
Popping and clicking sounds when you open your mouth could also indicate a problem. (Source: Daily Express - Health)
Source: Daily Express - Health - January 18, 2023 Category: Consumer Health News Source Type: news

The popular drink that could increase mouth cancer risk - labelled 'carcinogenic' by NHS
There are multiple risk factors for developing mouth cancer, including what you drink. (Source: Daily Express - Health)
Source: Daily Express - Health - January 11, 2023 Category: Consumer Health News Source Type: news

What to Know About Infusion Therapy for IBD
The human gastrointestinal tract can be a hostile place for visitors. It’s filled with digestive acids and microorganisms that rapidly break down swallowed bits of food, and it can be just as rough on non-food molecules. That includes some of the latest drugs for the treatment of inflammatory bowel disease (IBD). “Some medications that target the immune system don’t work if they’re swallowed because your gut would digest them like a piece of steak,” says Dr. Gilaad Kaplan, a gastroenterologist, IBD researcher, and professor of medicine at the University of Calgary in Canada. “You have to...
Source: TIME: Health - January 10, 2023 Category: Consumer Health News Authors: Markham Heid Tags: Uncategorized Source Type: news

‘Painful’ ulcers that do not heal can signal cancer, says doctor - regularly check mouth
Unusual lumps in the mouth and loose teeth are also signs that should be investigated, the doctor said. (Source: Daily Express - Health)
Source: Daily Express - Health - January 7, 2023 Category: Consumer Health News Source Type: news

DOACs vs Heparin in Cancer-Associated Thrombosis DOACs vs Heparin in Cancer-Associated Thrombosis
As compared with low-molecular-weight heparin, direct oral anticoagulants (DOACs) were more clinically effective and more cost-effective for treating cancer-associated thrombosis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 4, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Neoadjuvant Immunochemotherapy Promising in Oral SCC Neoadjuvant Immunochemotherapy Promising in Oral SCC
A small trial reported a 60% response rate to neoadjuvant immunochemotherapy in oral squamous cell carcinoma. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 29, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

How to Talk About HPV, Oral Sex, and Cancer With Patients How to Talk About HPV, Oral Sex, and Cancer With Patients
In the absence of clear indications from scientific authorities about how to broach the subject, clinicians must weigh the ethical implications of counseling.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 28, 2022 Category: Allergy & Immunology Tags: Infectious Diseases News Source Type: news

Network Meta-Analysis Compares DOACs to LMWH for Cancer-Linked Thrombosis
TUESDAY, Dec. 27, 2022 -- Direct oral anticoagulants (DOACs) are more effective and cost-effective than low-molecular-weight heparin for cancer-associated thrombosis (CAT), with the results sensitive to monthly drug costs, according to research... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 27, 2022 Category: Pharmaceuticals Source Type: news

Adagrasib Shows Anti-Tumor Activity in Heavily Pretreated KRAS-Mutant CRC
(MedPage Today) -- Adagrasib (Krazati) demonstrated antitumor activity in heavily pretreated patients with KRAS G12C-mutated, metastatic colorectal cancer (CRC), according to phase I/II study results. Monotherapy with the oral KRAS inhibitor led... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - December 21, 2022 Category: Gastroenterology Source Type: news

Science ’s 2022 Breakthrough of the Year: A telescope’s golden eye sees the universe anew
html { scroll-behavior: smooth; } .news-article-content--featured>.bodySection>.mb-2x:not(:first-of-type) { display: none; } h3 { scroll-margin-top: 5rem; } .parent-section h3, .subsection h3 { font-size: 1.375rem; line-height: 1.875rem; } .news-article-content-footer h2 { display: none; } .toc img { padding-bottom: 16px; transition: opacity .25s; } .toc img:hover { opacity: 60%; } .toc .image-grid img { padding-bottom: 16px; padding-top: 16px; } .image-grid .news-article__figure__image__wrapper:before, .image-grid .news-article__figure__image__wrapper:after { display: none; } .news-article...
Source: ScienceNOW - December 15, 2022 Category: Science Source Type: news

New Oral SERD Elacestrant -- for Which Breast Cancer Patients? New Oral SERD Elacestrant -- for Which Breast Cancer Patients?
New data from the pivotal trial elacestrant in patients with ER+/HER2- metastatic breast cancer show subgroups that get the greatest progression-free survival benefit.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news